share_log

Eli Lilly and Co | 8-K: Current report

Eli Lilly and Co | 8-K: Current report

禮來 | 8-K：重大事件
美股sec公告 ·  08/08 07:09
Moomoo AI 已提取核心訊息
Eli Lilly and Co (LLY) reported a significant increase in its financial results for the second quarter of 2024, with revenue surging 36% to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company's earnings per share (EPS) also saw a substantial rise, with reported EPS up 68% to $3.28 and non-GAAP EPS increasing 86% to $3.92. This performance led to an upward revision of the full-year revenue guidance by $3 billion and EPS guidance by $2.05 to $2.60. The quarter also marked progress in the company's pipeline, including the U.S. FDA approval of Kisunla for Alzheimer's disease and Jaypirca in Japan for mantle cell lymphoma. Additionally, the company submitted tirzepatide for obstructive sleep apnea and obesity in the U.S. and EU, and reported positive results from a Phase 3 trial for heart failure with preserved ejection fraction and obesity. Eli Lilly's financial outlook for 2024 has improved, with revenue guidance now ranging from $45.4 to $46.6 billion and EPS guidance between $15.10 to $15.60 on a reported basis, and $16.10 to $16.60 on a non-GAAP basis.
Eli Lilly and Co (LLY) reported a significant increase in its financial results for the second quarter of 2024, with revenue surging 36% to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company's earnings per share (EPS) also saw a substantial rise, with reported EPS up 68% to $3.28 and non-GAAP EPS increasing 86% to $3.92. This performance led to an upward revision of the full-year revenue guidance by $3 billion and EPS guidance by $2.05 to $2.60. The quarter also marked progress in the company's pipeline, including the U.S. FDA approval of Kisunla for Alzheimer's disease and Jaypirca in Japan for mantle cell lymphoma. Additionally, the company submitted tirzepatide for obstructive sleep apnea and obesity in the U.S. and EU, and reported positive results from a Phase 3 trial for heart failure with preserved ejection fraction and obesity. Eli Lilly's financial outlook for 2024 has improved, with revenue guidance now ranging from $45.4 to $46.6 billion and EPS guidance between $15.10 to $15.60 on a reported basis, and $16.10 to $16.60 on a non-GAAP basis.
禮來公司（LLY）報告稱，截至2024年第二季度，其財務業績顯著增長，營業收入大幅增長36％至113億美元，推動了蒙賈羅，捷邦德和維傑尼歐的強勁銷售。公司的每股收益（EPS）也實現了大幅增長，報告的EPS上升了68％至3.28美元，非GAAP EPS增長了86％至3.92美元。這個表現導致全年營業收入指導增加了30億美元，EPS指導增加了2.05美元至2.60美元。這個季度也標誌着該公司的管道進展，包括美國FDA批准Kisunla用於治療阿爾茨海默病和日本Jaypirca用於曼託細胞淋巴瘤。此外，該公司在美國和歐盟提交了Tirzepatide用於阻塞性睡眠呼吸暫停和肥胖病，並報告了有關心力衰竭和保留射血分數的肥胖症臨床3期試驗的積極結果。禮來公司2024年的財務前景已經改善，營業收入指導現在區間範圍從454億美元至466億美元，報告基礎EPS指導區間在15.10至15.60之間，非GAAP EPS指導區間在16.10至16.60之間。
禮來公司（LLY）報告稱，截至2024年第二季度，其財務業績顯著增長，營業收入大幅增長36％至113億美元，推動了蒙賈羅，捷邦德和維傑尼歐的強勁銷售。公司的每股收益（EPS）也實現了大幅增長，報告的EPS上升了68％至3.28美元，非GAAP EPS增長了86％至3.92美元。這個表現導致全年營業收入指導增加了30億美元，EPS指導增加了2.05美元至2.60美元。這個季度也標誌着該公司的管道進展，包括美國FDA批准Kisunla用於治療阿爾茨海默病和日本Jaypirca用於曼託細胞淋巴瘤。此外，該公司在美國和歐盟提交了Tirzepatide用於阻塞性睡眠呼吸暫停和肥胖病，並報告了有關心力衰竭和保留射血分數的肥胖症臨床3期試驗的積極結果。禮來公司2024年的財務前景已經改善，營業收入指導現在區間範圍從454億美元至466億美元，報告基礎EPS指導區間在15.10至15.60之間，非GAAP EPS指導區間在16.10至16.60之間。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息